Note: In Table 3 each row gives placebo n (%) and incidence rate per 100 patient-years, then REPATHA n (%) and incidence rate, then the hazard ratio (95% CI) for REPATHA vs placebo. The myocardial infarction, stroke, and coronary revascularization rows appear under "Other secondary endpoints" in Table 3, for which the label reports no p-values. Patients in FOURIER had established cardiovascular disease and were on statin therapy.
Note: Each row gives placebo (N = 13,780) n (%) and incidence rate per 100 patient-years, then REPATHA (N = 13,784) n (%) and incidence rate, then the hazard ratio (95% CI). FOURIER compared REPATHA 140 mg every 2 weeks or 420 mg once monthly with placebo, on a background of statin therapy, in patients with established cardiovascular disease over a median follow-up of 26 months.
Does Repatha reduce cardiovascular events without a prior heart attack or stroke (VESALIUS-CV)?
Note: In Table 4 each row gives placebo n (%), REPATHA n (%), and the hazard ratio (95% CI) for REPATHA vs placebo. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo on stable lipid-lowering background therapy over a median follow-up of 55 months.
Did Repatha lower the risk of death in VESALIUS-CV?
Note: Each row gives placebo (N = 6,100) n (%), REPATHA (N = 6,106) n (%), and the hazard ratio (95% CI). The digits after each endpoint name are footnote markers; footnote 2 marks the endpoints that did not meet statistical significance under the hierarchical testing procedure. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo every 2 weeks on stable lipid-lowering background therapy in adults at high cardiovascular risk without a prior myocardial infarction or stroke, followed for a median of 55 months.
Does Repatha reduce heart attacks in patients without a prior heart attack (VESALIUS-CV)?
Note: These are secondary endpoints of VESALIUS-CV (Table 4). Each row gives placebo (N = 6,100) n (%), REPATHA (N = 6,106) n (%), and the hazard ratio (95% CI); the letters and digits after each endpoint name are the footnote markers quoted below the rows. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo every 2 weeks on stable lipid-lowering background therapy in adults at high cardiovascular risk without a prior myocardial infarction or stroke, followed for a median of 55 months.
Study results
How much does Repatha lower LDL cholesterol in the cardiovascular outcomes trials?
Note: The first passage is from FOURIER (patients with established cardiovascular disease on statin therapy) and the second from VESALIUS-CV (patients at high cardiovascular risk without a prior myocardial infarction or stroke); both compare REPATHA with placebo. REPATHA was given as 140 mg every 2 weeks or 420 mg once monthly in FOURIER and as 140 mg every 2 weeks in VESALIUS-CV.